



A Results of HE and IHC




B Effect of Crizotinib Therapy


Baseline



Response to Crizotinib




Resistance to Crizotinib




Supplementary Figure 1. Histopathological diagnosis of the patient and image evaluation before and after crizotinib treatment.

A. Hematoxylin and eosin(H/E) staining and immunostaining for the left lung biopsy tissue. IHC analysis revealed that the tumor cells were positive for cytokeratin 7 (CK7), napsin A, and thyroid transcription factor-1 (TTF-1). B. CT or PET-CT images of the patient’s primary pulmonary and metastatic liver lesions chronicling the response to treatment with crizotinib.

A Effect of Ceritinib Therapy



B Effect of Lorlatinib combined with Crizotinib Therapy



Supplementary Figure 2. Image evaluation before and after the ALK inhibitors treatment.

A. CT or PET-CT images of the patient's primary pulmonary and metastatic liver lesions chronicling the response to treatment with ceritinib. B. PET-CT images of the patient's primary pulmonary and metastatic liver, lymph node, and bone lesions chronicling the response to combination treatment of lorlatinib with crizotinib.